Document is current
Any future updates will be listed below
-
Authors
Otiniano, Armelle
van de Wyngaert, Zoe
Brissot, Eolia https://orcid.org/0000-0003-4471-418X
Dulery, Rémy https://orcid.org/0000-0002-5024-1713
Gozlan, Joel
Daguenel, Anne
Abi Aad, Yasmine
Ricard, Laure
Stocker, Nicolas https://orcid.org/0000-0001-7316-5832
Banet, Anne
Bonnin, Agnes
Alsuliman, Tamim
Marjanovic, Zora
Schnuriger, Aurélie
Coppo, Paul
Legrand, Ollivier
Lacombe, Karine
Mohty, Mohamad https://orcid.org/0000-0002-7264-808X
Malard, Florent https://orcid.org/0000-0002-3474-0002
- License Information
-
More Information
Article History
Received: 29 September 2022
Revised: 24 November 2022
Accepted: 1 December 2022
First Online: 8 December 2022
Competing interests
: MM reports grants and lecture honoraria from Janssen, Sanofi, Maat Pharma and JAZZ pharmaceuticals, lecture honoraria from Celgene, Amgen, BMS, Takeda, and Pfizer, grants from Roche, all outside the submitted work. FM reports lecture honoraria from Therakos/Mallinckrodt, Janssen, Novartis, Gilead, Sanofi, JAZZ pharmaceuticals and Astellas, all outside the submitted work. The other authors declare no competing financial interests.
Free to read: This content has been made available to all.
